Caring Brands 3Q 2026: Revenue $0, EPS ($0.08) — 10-Q Summary

Caring Brands (CABR) reported no revenue for 3Q 2026, down from $740K a year earlier. Net loss narrowed 19% to $827K, with operating expenses falling 30%. Professional service fees declined 69%, while payroll expenses rose 96%. No sales were recorded for Emesyl, and licensing revenue timing remains uncertain.

Original reporting
Published Nov 13, 2026, 5:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Caring Brands 3Q 2026: Revenue $0, EPS ($0.08) — 10-Q Summary — source image
Decision brief

The 30-second read

$CABRBearishLow
01

Why it matters

For traders, the key signal is the combination of $0 revenue and no Emesyl sales/royalties in the quarter, partially offset by reduced operating expenses and a narrower loss.

02

Market read

This is a company-specific quarterly disclosure that can influence valuation via near-term revenue expectations and commercialization progress.

03

What to watch

The expanded SanPellegrino agreement adds territories for Photocil and Hair Enzyme Booster, but the filing emphasizes revenue timing remains subject to regulatory and contractual considerations, which may explain the $0 revenue quarter.

Relevance 5/10Novelty 4/10Timing: after-hours filing summary (Nov. 13, 2026)

Background

The piece is a brief summary of Caring Brands’ 10-Q filed Nov. 13, 2026, covering 3Q 2026 financials and commercialization/licensing updates.

Company-level read

Ticker impact

$CABRBearishMedium confidence
Context

Caring Brands’ 10-Q summary shows $0 revenue in 3Q 2026 and a diluted EPS loss of ($0.08), with operating expenses down 30%.

Expected impact

Likely downward pressure or continued weakness as investors focus on the lack of Emesyl sales and $0 revenue, despite lower operating expenses.

Evidence & confidence

The article’s primary new datapoints are the quarter’s $0 revenue and the absence of Emesyl commercialization activity, which directly affect revenue trajectory assumptions.

Market effects

Reinforces the high execution risk for small biopharma licensing/commercialization models when product sales are absent.

None indicated.

None indicated.

Counterpoint

The loss narrowing is driven by lower professional service fees, which could indicate cost discipline rather than deteriorating fundamentals, and licensing timing may be delayed rather than lost.

Key entities

  • Caring Brands, Inc.

    CABR, reported $0 revenue in the quarter, diluted EPS loss of ($0.08), and no Emesyl commercialization activity; also discussed expanded SanPellegrino agreement territories.

Related articles

$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.